Clover Biopharmaceuticals Ltd. (HK:2197) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clover Biopharmaceuticals Ltd. has announced positive preliminary results from their Phase I trial for their bivalent RSV vaccine candidate, SCB-1019, showing promising immunogenicity and safety in older adults. The vaccine, leveraging the company’s Trimer-Tag technology, demonstrated high neutralizing antibody titers and a favorable safety profile, with no serious adverse events reported. These results suggest SCB-1019 may offer a competitive edge in the global vaccine market, with full Phase I data expected by the end of 2024.
For further insights into HK:2197 stock, check out TipRanks’ Stock Analysis page.